ArticleThe Journal of neuroscience : the official journal of the Society for Neuroscience2007
Antibody-mediated clearance of amyloid-beta peptide from cerebral amyloid angiopathy revealed by quantitative in vivo imaging.
Article in The Journal of neuroscience : the official journal of the Society for Neuroscience, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 56 citations in OpenAlex.
- Early binding of anti-amyloid antibodies to CAA drives complement activation, inflammation and ARIA in mice.Molecular neurodegeneration · 2026Article
- Early Binding of Anti-Amyloid Antibodies to CAA Drives Complement Activation, Inflammation and ARIA in Mice.bioRxiv : the preprint server for biology · 2026Article
- Mouse models of Anti-Aβ immunotherapies.Molecular neurodegeneration · 2025Review
- Article
- Vaccination against β-Amyloid as a Strategy for the Prevention of Alzheimer's Disease.Biology · 2020Review
- Aβ Plaques.Free neuropathology · 2020Article
- Aβ43 in human Alzheimer's disease: effects of active Aβ42 immunization.Acta neuropathologica communications · 2019Article
- Article
- Outcome markers for clinical trials in cerebral amyloid angiopathy.The Lancet. Neurology · 2014Review
- Imaging of cerebrovascular pathology in animal models of Alzheimer's disease.Frontiers in aging neuroscience · 2014Review
- Four-dimensional microglia response to anti-Aβ treatment in APP/PS1xCX3CR1/GFP mice.Intravital · 2013Article
- Reducing available soluble β-amyloid prevents progression of cerebral amyloid angiopathy in transgenic mice.Journal of neuropathology and experimental neurology · 2012Article
- Chronic in vivo imaging in the mouse spinal cord using an implanted chamber.Nature methods · 2012Article
- Predicting cerebral amyloid angiopathy-related intracerebral hemorrhages and other cerebrovascular disorders in Alzheimer's disease.Frontiers in neurology · 2012Article
- A Peephole into the Brain: Neuropathological Features of Alzheimer's Disease Revealed by in vivo Two-Photon Imaging.Frontiers in psychiatry · 2012Article
- Resorufin analogs preferentially bind cerebrovascular amyloid: potential use as imaging ligands for cerebral amyloid angiopathy.Molecular neurodegeneration · 2011Article
- Cerebrovascular lesions induce transient β-amyloid deposition.Brain : a journal of neurology · 2011Article
- Cerebral amyloid angiopathy in the elderly.Annals of neurology · 2011Review
- Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: recommendations from the Alzheimer's Association Research Roundtable Workgroup.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2011Review
- Two-photon microscopy for chemical neuroscience.ACS chemical neuroscience · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
Abstract
Cerebral amyloid angiopathy (CAA) is the accumulation of amyloid-beta peptide (Abeta) in the vessel wall of arteries in the brain. Because CAA is commonly associated with Alzheimer's disease (AD), characterized by parenchymal deposition of the same peptide in the form of senile plaques, there is considerable interest in the relationship of the two deposits in generating human disease. The study of CAA is of particular importance for immunotherapeutic approaches to AD, because reports of anti-Abeta immunotherapy in mice and humans have suggested that, whereas CAA appeared resistant to clearance, its response to this treatment promoted potential adverse effects, including meningoencephalitis. We used multiphoton microscopy and longitudinal imaging to monitor CAA in a mouse model of amyloid deposition to evaluate the effects of anti-Abeta passive immunotherapy. We found detectable clearance of CAA deposits within 1 week after a single administration of antibody directly to the brain, an effect that was short-lived. Chronic administration of antibody over 2 weeks led to more robust clearance without evidence of hemorrhage or other destructive changes. We found that the progressive clearance of Abeta from vessels follows distinct kinetics from what has been previously reported for clearance of plaques (parenchymal deposits of Abeta). This quantitative in vivo imaging approach directly demonstrates that CAA in a transgenic mouse model can be cleared with an optimized immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.